Compare OFIX & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OFIX | IVVD |
|---|---|---|
| Founded | 1987 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 622.1M | 692.7M |
| IPO Year | N/A | 2021 |
| Metric | OFIX | IVVD |
|---|---|---|
| Price | $15.15 | $2.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $21.50 | $8.75 |
| AVG Volume (30 Days) | 190.2K | ★ 4.8M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $818,058,000.00 | $50,039,000.00 |
| Revenue This Year | $3.97 | $103.88 |
| Revenue Next Year | $5.84 | $171.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 4.31 | ★ 332.71 |
| 52 Week Low | $10.24 | $0.35 |
| 52 Week High | $20.48 | $3.07 |
| Indicator | OFIX | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 45.02 | 50.81 |
| Support Level | $14.88 | $2.52 |
| Resistance Level | $16.00 | $2.85 |
| Average True Range (ATR) | 0.45 | 0.20 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 25.82 | 29.52 |
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two main segments: global spine, including bone growth and healing therapies, spinal implants, and regenerative tissue products; and global orthopedics, providing products used in fracture repair, deformity correction, and bone reconstruction procedures. The majority of the company's sales come from the global spine segment in the United States. Orthofix distributes its products throughout North America, Europe, and several countries across the globe. The company provides solutions to hospitals, physicians, other healthcare providers, and patients.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.